Ebola virus (EBOV) infections often result in death, reflecting an inability of the host immune response to control virus replication. This may arise in part from the ability of EBOV to suppress dendritic cell function and to promote macrophage cytokine production, resulting in dysregulation of cellular antiviral responses [1] [2] [3] . Fatal cases also involve defective humoral responses to viral infection 4 . These viralinduced defects are largely due to the subversion of the host innate immune system by EBOV, which also contributes substantially to the high mortality rates associated with EBOV outbreaks 5 . RIG-I-like receptors (RLRs) are a central component of host innate immunity, as they detect viral nucleic acids during infection and replication [6] [7] [8] . Preactivation of RIG-I alone can inhibit virus replication and reduce virus growth up to ~1,000-fold, suggesting that inhibition of RLRs plays a substantial role in EBOV propagation 9 . Recently it has been shown that RLRs recognize and are activated by a variety of RNA ligands, including 5′-triphosphate (5′-ppp) and the blunt ends of dsRNA [10] [11] [12] [13] [14] . Viruses have also developed countermeasures to RLRmediated antiviral pathways, and the Ebola viral protein 35 (VP35) has recently emerged as a key viral component that can antagonize antiviral pathways activated by RLRs [15] [16] [17] [18] [19] [20] [21] [22] [23] .
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VOLUME 17 NUMBER 2 FEBRUARY 2010 nature structural & molecular biology a r t i c l e s biochemical and cell-biological studies. The structure of VP35 IID-dsRNA complex identified several conserved basic residues from VP35 IID that are important for protein-protein and protein-RNA interactions. IFN-β promoter assays show a strong correlation among residues that are important for dsRNA binding and those required for full IFN inhibition. Notably, residues that are important for IFN inhibition are not essential for viral polymerase cofactor function of EBOV VP35, suggesting that these two functions are likely to be carried out by distinct regions within VP35. Structurally predefined in vitro-transcribed (IVT) RNAs (short IVT dsRNA and IVT hairpin RNAs) with base-paired stems that are similar in length to those used in our structural studies can activate RIG-I-dependent IFN-β production. Additionally, VP35 IID can compete with RIG-I C-terminal RNA binding domain for short IVT dsRNA in vitro, and overexpression of EBOV VP35 can inhibit IFN-β signal activated by IVT dsRNA in vivo. Collectively, these studies support a mechanistic model in which dsRNA recognition and sequestration by Ebola VP35 prevents activation of host RLRs.
RESULTS

Central basic patch forms intermolecular interactions
We determined the structure of EBOV VP35 IID in complex with an 8-bp dsRNA using selenomethionine (SeMet)-labeled and native proteins. We solved both structures by molecular replacement using the ligand-free structure 32 (PDB 3FKE) as a search model ( Fig. 1 and Table 1 ). We used the corresponding unbiased map to build the dsRNA structure, and the electron density is shown in Supplementary  Figure 1 . The two complex structures were nearly identical, with r.m.s. deviation values <0.5 Å for all backbone atoms; therefore, the highestresolution structure (SeMet) was used for all subsequent analyses.
We observed four VP35 IID molecules and one 8-bp dsRNA in the crystallographic asymmetric unit. The complex structure shows two-fold noncrystallographic symmetry, where VP35 IID molecules A and B are equivalent to molecules C and D, respectively (Fig. 1a) . The VP35 IID molecules in the complex show limited structural perturbations relative to the ligand-free structure 32 (PDB 3FKE; r.m.s. deviation values < 0.5 Å). Molecules A and B (Fig. 1a,b) interact through a series of hydrogen bonds (Fig. 2a,b) . Arg312 from molecule A forms hydrogen bonds with Gly270 O, Asp271 Oδ1 and Glu269 O of molecule B. Arg322 of molecule A forms hydrogen bonds with residues Glu262 Oε1 and Oε2 as well as Glu269 Oε1 and Oε2 of molecule B. By symmetry, molecules C and D show similar interactions. Therefore, these conserved basic residues of molecules A and C form few solvent-mediated contacts with dsRNA. Other residues from molecules A and C (Pro233, Thr237, Phe239, Ser272, Gln274, Cys275, Ile278, Ala306, Lys309, Ser310 and Ile340) form van der Waals and water-mediated contacts with dsRNA. In contrast, the side chains of Arg312 and Arg322 in molecules B and D form direct contacts with the phosphodiester backbone of dsRNA (Fig. 2c,d ) (Arg312 NH1 and NH2 to U5 O1P and O2P as well as G8 O2P, and Arg322 NH2 to G6 O1P and C7 O2P). In the absence of base-specific contacts, it is likely that the interactions observed between the VP35 IID central basic patch and the 8-bp dsRNA are independent of the nucleotide sequence. Collectively, the protein-protein and protein-RNA interactions observed in the complex suggest that the central basic patch may function in both dsRNA-independent and dsRNA-dependent VP35-mediated functions. Notably, the conformations of the main chains are similar, which suggests that the functional versatility of the residues in the EBOV VP35 IID is mediated through modulation of side chain conformations (Supplementary Table 1) .
Isothermal titration calorimetry (ITC) experiments reveal that the 8-bp dsRNA used in the structural studies binds VP35 IID with high affinity (K d = 500 nM) and a stoichiometry of 4:1 VP35 IID to dsRNA, which is consistent with the number of molecules in the crystallographic complex (Fig. 1c) . ITC assays with IVT 8-bp dsRNA containing 5′-ppp revealed that VP35 IID binds with higher affinity (K d,1 = 30 nM, K d,2 = 2.2 µM with 1 and 3 binding sites, respectively), which corroborates the stoichiometry observed in the complex structure (Supplementary Fig. 2a) . However, VP35 IID does not bind singlestranded RNA (Fig. 1d) .
We previously identified two distinct conserved basic patches located in the α-helical and β-sheet subdomains of the VP35 IID, termed the first and central basic patch, respectively 32 . Gel-shift analyses indicate that only the latter patch is important for dsRNA interactions. Consistent with this finding, only residues from the central basic patch interact with dsRNA in the VP35 IID-dsRNA complex structure. The importance of basic residues in dsRNA recognition was further assessed by ITC studies. Mutation of Arg305 or Lys319 to alanine results in a reduction in the binding affinity relative to WT protein by a factor of 3-5 ( Supplementary Fig. 2b ). In contrast, proteins containing an R312A, R322A or K339A mutation failed to bind dsRNA (Supplementary Fig. 2c) . These results Fig. 3a) .
Comparison of side chain conformations, particularly near the central basic patch, did not reveal a direct correlation between loss of dsRNA binding and mutations affecting basic residues (Supplementary Fig. 3b ). For example, the main chain conformation of the R312A mutant protein is nearly identical to that of the WT structure. However, electrostatic distribution of solvent-accessible surfaces of the mutant proteins revealed appreciable differences near regions that make contact with protein and dsRNA in the complex, suggesting that observed functional differences are likely to be due to changes in surface-charge distribution at specific sites ( Fig. 3a-c) . In contrast, evaluation of the in silico modeling of the R305A, K309A and K319A mutant structures suggest that these mutations are unlikely to cause substantial changes in the electrostatic surface within the interaction 'footprint' defined by the VP35 IID-dsRNA complex ( Supplementary Fig. 4) . These results support a model in which Arg312, Arg322 and Lys339 make critical contributions to dsRNA recognition and binding, whereas Arg305, Lys309 and Lys319 enhance the key interactions (Fig. 3d) . In the crystal structure of the complex, both Arg312 and Arg322 make direct RNA contacts, whereas Lys339 does not directly bind to dsRNA.
Comparison of the K339A mutant structure to the WT VP35 IID structure revealed that the Lys339 side chain coordinates the carboxylate group of the terminal residue, Ile340 (Supplementary Fig. 5 ), leading to charge neutralization. Mutation of Lys339 exposes a negative charge at the C-terminus, which is likely to introduce unfavorable interactions near the central basic patch and reduced dsRNA binding.
Hydrophobic residues end-cap dsRNA
In the structure of the VP35 IID-dsRNA complex, several conserved hydrophobic residues at the intersubdomain interface form a previously unrecognized end cap that interacts with the dsRNA ends (Fig. 4) . Hydrogen bonds form between Gln274 Nε and C1 O4′ as well as between Ile340 OXT and C1 N4. Additional protein-dsRNA interactions include electrostatic interactions between Lys282 Nζ and G8 O2P as well as between Arg322 Nε and C7 O2P; and van der Waals contacts between Phe239 Cζ and Cε2 to C6, Gln274 Cγ to C6 O4′, Ile278 Cδ1 to G8 N1 and C6, Gln279 Cδ to G8 O3′, Gln279 Oε1 to G8 C2′, C3′ and O3′, and Lys282 Cε to G8 O2P and O5′. Recognition of short dsRNA by RLRs leads to potent activation of antiviral signaling pathways, including IFN-β production 11, 13 . Extensive interactions observed in our VP35 IID-dsRNA complex structure strongly suggest that VP35 IID is able to recognize blunt-end conformations of short duplex RNA similar to those observed for RLRs 14, 34 . 
a r t i c l e s
We tested the importance of the end-cap interaction in dsRNA binding through mutation of residues that form the end-cap structure. ITC-based RNA binding assays for F235A and F239A revealed that mutation of Phe239 but not Phe235 results in a complete loss of dsRNA binding (Supplementary Fig. 6 ). These results are consistent with the structure of the complex, where Phe239 is part of the end cap and forms van der Waals contacts with both dsRNA and terminal Ile340 from the β-sheet subdomain. Phe235 is outside the end-cap structure. Solution NMR analysis of the F239A mutant reveals that the mutation causes modest chemical-shift perturbations (within 6-8 Å of the site of mutation), where a majority of the structure is largely unperturbed (data not shown). Together, these results suggest that limited structural changes in the main chain are caused by mutation of end-cap residues. Therefore, the observed loss of dsRNA binding is likely to be due to the loss of intermolecular contacts between the side chains of the VP35 IID and the blunt ends of dsRNA.
Shape and charge complementarity in the complex
Shape and charge complementarity analyses support the existence of the protein-protein and protein-RNA interactions observed in the complex structure. The calculated shape correlation statistics (S c , a measure of the geometric match of two interacting surfaces) 35 are buried through interactions between the VP35 IID proteins and the 8-bp dsRNA. Of the ~6,300 Å 2 total available surface area for each VP35 IID molecule in the complex, about 400 Å 2 are contacting the dsRNA. In contrast, ~1,400 Å 2 are in contact at the proteinprotein interface, suggesting that protein-protein interactions make substantial contributions toward the complex formation. These protein-protein interactions are more important than those seen at the crystallographic dimer interface for ligand-free WT VP35 IID 32 . Together, these data highlight the ability of VP35 IID to facilitate intermolecular interactions in a context-dependent manner with limited backbone conformational changes. Given that the same VP35 IID-dsRNA complex appears in two different space groups (Table 1) , crystal packing has little or no effect on the interactions observed in the complex. This notion is further supported by solution NMR data for the VP35 IID bound to dsRNA, where residues showing the largest chemical-shift differences upon RNA addition are involved in dsRNA recognition in the crystal structure (data not shown).
Inhibition of dsRNA-independent IFN-β activation by VP35
To test the inhibition of dsRNA-independent IFN-β activation by VP35, we measured activation of IFN-β mediated by the RIG-I caspase recruitment domain (CARD). RIG-I CARDs activate the IFN-β promoter when overexpressed 12 . This method of IFN-β promoter activation presumably does not require RNA ligands to activate antiviral signaling. Transfection of WT VP35 reduces the IFN-β response generated by RIG-I CARDs by about 65%. Mutation of residues involved in the dsRNA end-cap recognition (F239A and H240A) also suppresses IFN-β promoter activation to levels similar to those for (Supplementary Fig. 7a ). In contrast, central basic patch mutants (R312A, R322A and K339A) show reduced suppression of IFN-β promoter activation (Supplementary Fig. 7b) . Notably, end-cap residues only show protein-dsRNA intermolecular interactions in the complex structure, and they are not involved in protein-protein interactions such as those observed for the central basic patch residues (Figs. 2 and 4 ). These results demonstrate that when the IFN-β promoter is activated by a dsRNA-independent mechanism, VP35 is also able to partially suppress this activation. This residual suppression does not require dsRNA binding by VP35, as F239A and H240A mutants cannot bind dsRNA. Therefore, the reduced IFN-β inhibition shown by VP35 proteins containing mutations at residues Arg312, Arg322 and Lys339 is likely due to VP35-mediated protein-protein interactions. However, the relative contributions to dsRNA-dependent and -independent functions cannot be directly determined, as residues in the central basic patch are involved in both types of interactions.
Inhibition of dsRNA-dependent IFN-β activation by VP35
Multifunctional Ebola VP35 is a cofactor for the viral polymerase L in addition to its role as an IFN antagonist. Therefore, we performed a series of in vivo experiments to evaluate the importance of residues that show intermolecular contacts in the complex structure. To this end, we assessed the viral polymerase cofactor function in the context of full-length VP35 expressed in 293T cells. The viral transcription and replication complex is reconstituted by coexpression of EBOV NP, VP35, VP30 and L proteins such that the complex transcribes and replicates a coexpressed model viral genome encoding only reporter genes 36 . VP35 proteins containing mutations in the end cap (F239A) or the central basic patch (R305A, K309A, R312A, K319A, R322A or K339A) were functional in a 'minigenome' assay, which measures the activity of the viral RNA polymerase complex. Absolute levels of activity, however, showed some variation. These differences were either due to reduced expression levels of some mutant VP35 proteins relative to WT VP35 (Table 2, Supplementary Fig. 8 ) or due to different levels of polymerase cofactor activity of the mutants. The latter possibility is currently being assessed. Notably, end-cap mutant F235A, which retains dsRNA binding, was nonfunctional in the minigenome assay despite expression levels comparable to WT VP35. H240A also did not show any activity, but its poor level of expression may explain this absence of activity (data not shown). Together, these data suggest that the ability of VP35 to function as a viral polymerase cofactor is not dependent on the residues that are important for dsRNA binding.
We next characterized IFN inhibition by VP35.
To this end, we tested the inhibition of Sendai virus-mediated activation of the IFN-β promoter by WT and mutant VP35 proteins, which contained mutations within the VP35 IID (Fig. 5, Supplementary Fig. 9 ). These results revealed that end-cap and central basic patch residues are important a r t i c l e s in the inhibition of IFN-β activation but not those from the first basic patch. VP35 mutants that failed to bind dsRNA (F239A, R312A, R322A and K339A) were also unable to suppress the IFN-β promoter activation relative to WT VP35 (Table 2, Supplementary Fig. 9 ). Additional residues tested, including F235A, R305A, K309A and K319A, showed reduced but measurable dsRNA binding activity and were able to suppress IFN-β reporter expression, but they did so less efficiently than WT VP35. These results show a strong correlation with dsRNA binding data ( Table 2 , compare columns 1 and 2).
VP35 can inhibit RIG-I activation by dsRNA
The data presented above support a model in which dsRNA recognition by VP35 leads to dsRNA sequestration and may result in substantially diminished activation of cellular RLRs. To further test this model, we characterized the ability of VP35 to bind to RIG-I ligands using IVT dsRNA that contains the 5′-ppp motif 11, 13 . Corresponding ITC data (Supplementary Fig. 2a ) revealed that the VP35 IID can bind IVT 8-bp dsRNA with affinities similar to those observed for RIG-I-dsRNA binding 11 . Notably, these binding affinities were higher than those observed for chemically synthesized 8-bp dsRNA that contains a 5′-OH motif (Fig. 1c) , suggesting a preference for a 5′-ppp moiety that is contained in IVT dsRNA. Next, the ability of VP35 IID to bind and compete for IVT dsRNA in the presence of the RIG-I C-terminal domain was assessed by NMR. Using 1 H-and 15 N-labeled VP35 IID, we monitored two-dimensional heteronuclear single-quantum coherence (HSQC) NMR signals for VP35 IID protein alone, as well as for VP35 IID protein upon addition of either dsRNA, dsRNA + RIG-I C-terminal domain (competition experiment) or RIG-I C-terminal domain only (negative control). Addition of dsRNA reduced the NMR signal intensity of the VP35 IID due to an increase in molecular size upon binding dsRNA (average intensity = 0.36 ± 0.1) (Fig. 6a-d) . Notably, addition of the RIG-I C-terminal domain, which has been shown to bind dsRNAs similar in length and structure to those used in our studies 33, 37 , into the binary complex at equimolar concentrations did not lead to a complete reversal of peak intensities for the VP35 IID (average intensity = 0.42 ± 0.1). These data suggest that the RIG-I C-terminal domain cannot completely displace (and, therefore, compete with) the VP35 IID for dsRNA binding. VP35 IID peak intensities were also measured upon addition of RIG-I C-terminal domain as a negative control (average intensity = 0.92 ± 0.1), which revealed that RIG-I and the VP35 IID do not interact with each other in the absence of dsRNA.
Next, we used structurally predefined dsRNAs to activate RIG-I-specific signaling cascades in order to examine the effect on IFN-β promoter activation by VP35. IVT dsRNA and IVT hairpin RNAs (similar to those used in previous work 13 ), including stems as short as those containing 8 bp, activated the IFN-β promoter in 293T cells transfected with a RIG-I expression plasmid (Fig. 6e,f) . Notably, the IVT hairpin RNA consistently activated the IFN-β promoter to a higher level than the IVT 8-bp dsRNA. Our results also showed that a 5′-ppp was required for dsRNA-mediated IFN-β activation. Cotransfection of WT VP35 inhibited IVT dsRNA-dependent RIG-I activation. Collectively, our data suggest that (i) the IVT dsRNA with lengths similar to that used in our structural study can activate IFN-β activity, (ii) the IFN-β promoter can be specifically activated by transfection of IVT dsRNA recognized by RIG-I and (iii) VP35 can inhibit IVT dsRNA-dependent activation of IFN-β mediated by RIG-I.
DISCUSSION
The combination of structural, biochemical and cell-biological studies described here provide a strong correlation between the ability of the VP35 IID to bind dsRNA and to inhibit IFN-β promoter activation. Specifically, we show that residues in the central basic patch and those that form the end cap in VP35 IID are important for dsRNA binding. Crystal structures of R312A and K339A show minor structural perturbations in the main chain but substantial changes in surface electrostatics near the dsRNA binding site, suggesting that side chain rearrangements may be responsible for loss of dsRNA binding by these mutants. We show that in vitro-transcribed RNA (IVT 8-bp dsRNA and IVT hairpin) with stems as short as 8 bp can activate the IFN-β promoter in a RIG-I-specific manner 11, 13 .
Corresponding in vivo studies of VP35 mutants suggest that many residues that are important for dsRNA binding and for inhibition of IFN-β promoter activity also function through additional proteinprotein interactions, which may be important for downstream signaling. Specifically, we show that dsRNA-independent IFN-β activation is significantly diminished when central basic patch-residue mutants are tested, but the end-cap mutants are functional in the same assay, providing further support for the existence of dsRNA-independent IFN antagonism by VP35 (refs. 38,39) .
RLRs 18 and RNA-dependent protein kinase PKR 25 are important antiviral RNA sensors that can limit EBOV replication. Preactivation of RIG-I decreases EBOV replication, which supports the importance a r t i c l e s of RIG-I signaling in EBOV pathogenesis 9 . Short dsRNAs and dsRNA containing 5′-ppp are putative activators of RLRs and PKR [40] [41] [42] [43] [44] .
Comparison of our structure to the RLR LGP2 in complex with dsRNA revealed that both VP35 and LGP2 recognize similar structural features in dsRNA 34, 43 (Supplementary Fig. 10 ). RIG-I, MDA5 and PKR also bind to and are activated by blunt-end RNAs, suggesting that this recognition mode may be commonly used by dsRNA-sensing pattern-recognition receptors 7, 34, 37, 41, 43, 44 . Moreover, the VP35 IID can bind IVT 8-bp dsRNA with affinities similar to those previously observed for RIG-I 13,34,37 . The RNA binding domain at the C terminus of RIG-I and the VP35 IID both have higher affinities for 5′-ppp dsRNA than for 5′-OH dsRNA of similar length and sequence, supporting the proposal that dsRNA containing 5′-ppp is a more potent activator of the RIG-I pathway. However, it is important to note that 5′-OH dsRNA can also bind the C-terminal domain of RIG-I 13,34,37 and VP35 (D.W.L., G.K.A. and C.F.B., unpublished data). Therefore, previously published data as well as our own observations support a model in which wide variation in the affinities for different RNA ligands results in a greater response range that may correspond to the relative availability of these ligands. For example, RLRs bind with higher affinity to 5′-ppp-containing dsRNA (for example, 10-100 nM for RIG-I, MDA-5 and LGP2) 13, 34, 37 , but they also bind dsRNA lacking 5′-ppp 13, 34, 37 . Our data reported here for VP35 and those previously characterized for RLRs indicate that for a given ligand (either 5′-ppp dsRNA or 5′-OH dsRNA), the affinities of the VP35 IID and the RLR C-terminus are similar. Therefore, given that large amounts of VP35 would be produced in EBOV-infected cells, VP35 likely competes with RIG-I for these RNA ligands. Moreover, fulllength VP35 is a trimer, which will likely have even higher binding affinities due to multivalency. It is interesting to note that the relative affinities for different RNA ligands qualitatively correspond to their availability in infected cells, where more dsRNA is likely available than 5′-ppp dsRNA ends. The ability of cellular RLRs to respond to a wide range of ligand affinities enables these key antiviral receptors to detect multiple viral signals, which would enable signal integration at RIG-I, leading to a more potent downstream signal and activation of IFNs. Mechanisms described in our study for dsRNA-dependent IFN antagonism by VP35 are likely to be important contributors to Ebola viral pathogenesis, as the end-cap mutants are unable to suppress dsRNA-dependent pathways yet can suppress dsRNA-independent activation, as shown in the RIG-I CARD assays. Therefore, competition between Ebola VP35 IID and cellular RNA sensors for similar RNA ligands emerges as a potential mechanism for facilitating VP35-mediated immune evasion. VP35 is part of a growing list of viral antagonists of host immunity that mimic cellular components. In addition to dsRNA-dependent activity described here, multifunctional VP35 also uses dsRNAindependent functions that target other elements in the RLR signaling pathway 38, 39 . This may be reflected by the residual inhibition seen for WT and end-cap mutants of VP35 when RIG-I CARDs were used to activate the IFN-β promoter independently of dsRNA. Similarly, both WT and R312A mutant VP35 proteins can partially inhibit IFN-α and IFN-β production induced by overexpression of IPS-1, TBK-1 or IKKε 17 . VP35 also associates with IRF-3 kinases and competes for the IRF-3 substrate binding site on IKKε or TBK-1 in order to prevent IRF-3 phosphorylation 39 . Therefore, mechanisms that target additional elements within cellular antiviral pathways likely contribute to EBOV immune evasion. Full knowledge of interactions between host factors and VP35 through future studies will facilitate the development of vaccines and antivirals against an indispensible component from a highly pathogenic virus and a potential agent of bioterrorism.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Accession codes. Protein Data Bank: Coordinates and structure factors have been deposited under accession numbers 3L25 (SeMet VP35 IID-8-bp dsRNA complex), 3L26 (native VP35 IID-8-bp dsRNA), 3L27 (VP35 IID R312A mutant) and 3L28 (VP35 IID K339A mutant).
ONLINE METHODS
Generation of material.
We expressed and purified the recombinant protein encoding VP35 IID corresponding to the amino acid sequence from Zaire Ebola virus (strain Mayinga-76) 32, 45 and RIG-I C terminus 43 proteins as described previously. We purchased all RNA samples from IDT Technologies, and the samples were desalted before use. For 8-bp dsRNA, we used 5′-CGCAUGCG-3′ and 5′-GGCAUGCC-3′ sequences. Only IVT 8-bp dsRNA (5′-GGCAUGCC-3′) and in vitro-transcribed (IVT)-hairpin RNA (hp2.2s/as sequence 13 ) were prepared by in vitro transcription. We generated IVT RNA by using synthetic DNA templates containing T7 RNA polymerase promoter. We purified RNA transcripts containing 5′-ppp from aborted transcripts following published protocols 46 . We purified IVT 8-bp dsRNA over a Superdex 75 (10/300 GL) column and IVT hairpin RNA using a Superdex 200 (10/300 GL) column. We used antibodies for VP35 as previously described 17 .
Crystallization and structure determination. We identified initial conditions for crystallization of proteins using commercial screens (Hampton Research) and optimized these conditions in house. For the VP35 IID-dsRNA complex, we mixed dsRNA samples at either 1:1.2 or 1:2 (ratio of VP35 IID:dsRNA) and incubated them for 10 min at 25 °C before crystallization. We grew SeMet and native crystals at 25 °C using the hanging drop vapor diffusion method with a 1:1 dilution of 7 mg ml −1 VP35 IID with 1:1.2 or 1:2 dsRNA solutions. For the mutant proteins, we grew crystals with a 1:1 dilution of 26 mg ml −1 of R312A or 10 mg ml −1 of K339A protein. We soaked crystals in a reservoir solution with 25% (w/v) glycerol before flash freezing. We collected diffraction data at the Advanced Light Source (Beamline 4.2.2) and at the Advanced Photon Source (Sector 19) at 100 K ( Table 1) .
We processed data using HKL2000 (ref. 47) or d*TREK 48 . We converted intensities to structure factors using the CCP4 program 49 TRUNCATE. We determined phases using molecular replacement with the native wild-type structure of VP35 IID 45 (PDB 3FKE) using either MOLREP 50 Table 1 . We calculated buried surface area and surface complementarity using AREAIMOL 58 and S c 35,49 , respectively. We performed validation of the structure using SFCHECK and PROCHECK 49 . We prepared figures using PyMOL 59 .
ITC RNA binding assays. We measured affinities between VP35 IID proteins and RNA using a VP-ITC microcalorimeter (Microcal). We dialyzed all samples against 1 l of 10 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM MgCl 2 and 2 mM (tris(2-carboxyethyl)phosphine) (TCEP) over 12 h with two buffer changes before use. We processed raw ITC data and fit the data by nonlinear least-squares analysis to yield n (number of binding sites), K D (equilibrium binding constant), and ∆H (change in enthalpy of reaction) using ORIGIN software. We carried out ITC experiments for IVT RNA similarly, except the RNA was used directly from the peak fractions of the size-exclusion chromatographic columns.
Replication and transcription assays. We used the minigenome system as described previously 36 . We cotransfected 293T cells by calcium phosphate precipitation method with T7-driven expression plasmids encoding Zaire EBOV NP, VP35, VP30 and L proteins. We also transfected a T7 RNA polymerase expression plasmid, a T7 promoter-driven Zaire EBOV minigenome encoding a green fluorescence protein (GFP) gene fused to a chloramphenicol acetyl transferase (CAT) gene-containing plasmid and a firefly luciferase expression plasmid as a control for transfection efficiency. We lysed cells 36 h after transfection. We determined CAT and firefly luciferase activities and normalized CAT activity to luciferase activity. We set results from 250-ng transfections of wild-type VP35 to 100% activity. Error bars represent the s.d. for at least three experiments.
Reporter gene assays. We performed all reporter gene assays on 293T cells and we used a Dual Luciferase Reporter assay (Promega). We normalized firefly luciferase activity to Renilla luciferase activity, and we expressed the results as percent induction relative to the positive control. Error bars represent the s.d. for three independent experiments.
To measure IFN-β promoter activation, we transfected VP35 expression plasmid, 400 ng of IFN-β promoter-firefly luciferase reporter plasmid and 200 ng of a constitutively expressed Renilla luciferase reporter plasmid by the calcium phosphate method. After 12 h, we either mock-infected transfected cells or infected them with Sendai virus strain Cantell (multiplicity of infection (m.o.i.) = 5). We prepared lysates 12 h after infection.
To test RNA-independent IFN-β activation, we transfected cells with 400 ng of IFN-β promoter-firefly luciferase reporter plasmid and 200 ng of a constitutively expressed Renilla luciferase reporter plasmid, as well as either 50 ng of RIG-I CARD domain expression plasmid or 50 ng of empty vector. We also cotransfected an additional 500 ng of either empty vector or of VP35 expression plasmid. We prepared lysates 24 h after transfection.
To measure dsRNA activation of the IFN-β promoter, we transfected 36 ng of hemagglutinin peptide (HA)-tagged RIG-I plasmid, the indicated amounts of VP35 expression plasmid, 300 ng of IFN-β promoter-firefly luciferase reporter plasmid and 100 ng of a constitutively expressed Renilla luciferase reporter plasmid using Lipofectamine 2000 (Invitrogen). After 8 h, we transfected the cells by the calcium phosphate precipitation method with 4 µg of 8-bp dsRNA, IVT 8-bp dsRNA or IVT hairpin RNA. We prepared lysates 24 h later.
VP35-RIG-I competition NMR assays.
We acquired all experiments at 25 °C on a Bruker Avance II spectrometer (700.13 MHz with a 5-mm z-axis field gradient and triple inverse gradient (TXI) cryoprobe). We processed data with NMRPipe/ NMRDraw 60 and analyzed data using NMRView 61 . We prepared samples in 95% H 2 O/5% D 2 O aqueous buffer containing 10 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM MgCl 2 and 2 mM TCEP. Four 1 H/ 15 N HSQC experiments were collected for VP35 IID alone, VP35 IID with IVT 8-bp dsRNA, V35 IID with IVT 8-bp dsRNA and RIG-I C terminus (residues 792-925) and VP35 IID with RIG-I C terminus. VP35 and RIG-I concentrations were 50 µM and dsRNA concentration was 12.5 µM.
